Milestone Pharmaceuticals (NASDAQ:MIST) Trading 0.7% Higher

Milestone Pharmaceuticals Inc. (NASDAQ:MIST)’s share price rose 0.7% on Tuesday . The stock traded as high as $1.55 and last traded at $1.53. Approximately 159,886 shares traded hands during trading, a decline of 26% from the average daily volume of 215,921 shares. The stock had previously closed at $1.52.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on MIST. Rodman & Renshaw began coverage on shares of Milestone Pharmaceuticals in a research report on Thursday, August 22nd. They issued a “buy” rating and a $9.00 target price for the company. HC Wainwright reaffirmed a “buy” rating and issued a $25.00 price objective on shares of Milestone Pharmaceuticals in a research note on Thursday, August 22nd.

Milestone Pharmaceuticals Stock Performance

The stock has a fifty day moving average price of $1.45 and a 200 day moving average price of $1.54. The company has a current ratio of 19.13, a quick ratio of 19.13 and a debt-to-equity ratio of 1.61. The firm has a market cap of $81.49 million, a price-to-earnings ratio of -1.22 and a beta of 1.71.

Milestone Pharmaceuticals (NASDAQ:MIST) last announced its earnings results on Thursday, August 8th. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.05. As a group, analysts predict that Milestone Pharmaceuticals Inc. will post -0.71 earnings per share for the current year.

Hedge Funds Weigh In On Milestone Pharmaceuticals

A hedge fund recently raised its stake in Milestone Pharmaceuticals stock. Lion Point Capital LP raised its stake in shares of Milestone Pharmaceuticals Inc. (NASDAQ:MIST) by 1.7% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 2,340,207 shares of the company’s stock after acquiring an additional 40,000 shares during the quarter. Milestone Pharmaceuticals makes up 5.6% of Lion Point Capital LP’s portfolio, making the stock its 3rd largest holding. Lion Point Capital LP owned about 4.39% of Milestone Pharmaceuticals worth $3,089,000 as of its most recent filing with the SEC. Institutional investors own 86.18% of the company’s stock.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.